Aging & Elder Health Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Aging & Elder Health Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Chugai Pharmaceutical Co. Ltd
Picibanil shows promise as adjuvant for dendritic cell vaccines
January 9th, 2005
Picibanil shows promise as an adjuvant for dendritic cell vaccines. "OK-432 (Picibanil), a streptococcal preparation with potent biological response modifying activities, was approved in Japan as an anticancer agent in 1975. In the ensuing 30 years, since then, a significant amount of data, including clinical as well as experimental studies, has been accumulated. OK-432 has been reported to induce various cytokines, activate immunological cells and thus augment anticancer immunity," scientists in Japan report. "Recently, the interrelation between innate immunity and adaptive immunity has become clear and it was reported that OK-432 acts, at least in...
Source: Aging & Elder Health Week (2005-01-09)
|
